Dispatches from BPI Europe 2016

Roche: Bispecific and complex mAbs driving process development

By Dan Stanton

- Last updated on GMT

Roche: Bispecific and complex mAbs driving process development

Related tags Bispecific antibodies Monoclonal antibodies

The increasing complexity of biopharmaceuticals is driving process development innovation according to Swiss drug firm Roche.

The methods used to make blockbuster monoclonal antibodies like Herceptin and Avastin are not sufficient to produce next generation biopharmaceuticals according to Wolfgang Kuhne, Roche’s VP of technical development bioprocessing.

He told delegates at the Bioprocess International European Summit in Vienna, Austria that making candidates like ACE910 – a bispecific antibody granted breakthrough designation for haemophilia last September​ – had required a considerable process development effort.

“There are no more classical standard approaches and we have to make a huge effort for our bioprocessing development,”​ he said.

Downstream challenges

The initial stages of making bispecific antibodies are very similar to those used to make ‘simpler’ drugs like Herceptin.

The molecules are produced in bioreactors by cultured Chinese Hamster Ovary (CHO) cells.

The challenge, Kuhne continued, had been the development of purification processes capable of harvesting the innovative molecules.

Established technologies like Protein-A based resins had not proved effective he said, adding that processes like virus removal are also more complex for bispecific antibodies than for mAbs.

Related news

Show more

Related products

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...